Stay updated on Subcutaneous Lirentelimab in Urticaria: Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page.

Latest updates to the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded Revision: v3.4.2 and removed the prior government funding operating-status notice (and Revision: v3.4.1). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check20 days agoChange DetectedNew site-wide notice about government funding and NIH Clinical Center status appears, and the page revision is updated to v3.4.1; core study content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check28 days agoChange DetectedShow glossary toggle was added and a revision indicator (Revision: v3.4.0) appears on the page. QC-related labels and policy wording were updated (e.g., 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data').SummaryDifference0.1%

- Check42 days agoChange DetectedThe page now shows Revision: v3.3.4, replacing Revision: v3.3.3. This update appears to be a metadata/version tag and does not modify core study content.SummaryDifference0.0%

- Check63 days agoChange DetectedAdded a Locations section listing multiple U.S. states as study sites and updated the revision to v3.3.3; the prior v3.3.2 location listings and the HHS disclosure item were removed.SummaryDifference2%

- Check92 days agoChange DetectedRevision: v3.3.2 was added to the study documents, replacing the previous Revision: v3.2.0.SummaryDifference0.0%

Stay in the know with updates to Subcutaneous Lirentelimab in Urticaria: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page.